Eiropas Savienība - latviešu - EMA (European Medicines Agency)

celgene europe bv - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfomas b-Šūnu - antineoplastiski līdzekļi - polivy kopā ar bendamustine un rituksimabs ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed/ugunsizturīgi difūza liela b-šūnu limfoma (dlbcl), kas nav kandidātu hematopoētisko cilmes šūnu transplantācijas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiski līdzekļi - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multiple mieloma - antineoplastiski līdzekļi - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatas audzējiem, kastrācija-izturīgs - antineoplastiski līdzekļi - treatment of adult patients with prostate cancer.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - crisantaspase - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imūnsupresanti - lūdzu, skatiet 4. sadaļu. produkta raksturojuma kopsavilkums 1 produkta informācijas dokumentā.

Latvija - latviešu - Zāļu valsts aģentūra

orion corporation, finland - varfarīna nātrija sāls - tablete - 3 mg

Latvija - latviešu - Zāļu valsts aģentūra

orion corporation, finland - varfarīna nātrija sāls - tablete - 5 mg